Harbin Gloria Pharmaceuticals (002437) - Total Assets
Based on the latest financial reports, Harbin Gloria Pharmaceuticals (002437) holds total assets worth CN¥3.14 Billion CNY (≈ $459.71 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Harbin Gloria Pharmaceuticals - Total Assets Trend (2007–2025)
This chart illustrates how Harbin Gloria Pharmaceuticals's total assets have evolved over time, based on quarterly financial data. Also see Harbin Gloria Pharmaceuticals market capitalisation for the company's overall valuation and market capitalisation.
Harbin Gloria Pharmaceuticals - Asset Composition Analysis
Current Asset Composition (December 2025)
Harbin Gloria Pharmaceuticals's total assets of CN¥3.14 Billion consist of 42.1% current assets and 57.9% non-current assets. Review Harbin Gloria Pharmaceuticals (002437) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 12.7% |
| Accounts Receivable | CN¥126.61 Million | 4.0% |
| Inventory | CN¥205.88 Million | 6.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥170.95 Million | 5.5% |
| Goodwill | CN¥369.03 Million | 11.8% |
Asset Composition Trend (2007–2025)
This chart illustrates how Harbin Gloria Pharmaceuticals's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Harbin Gloria Pharmaceuticals stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Harbin Gloria Pharmaceuticals's current assets represent 42.1% of total assets in 2025, a decrease from 52.3% in 2007.
- Cash Position: Cash and equivalents constituted 12.7% of total assets in 2025, down from 19.2% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 8.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 11.8% of total assets.
Harbin Gloria Pharmaceuticals Competitors by Total Assets
Key competitors of Harbin Gloria Pharmaceuticals based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
Harbin Gloria Pharmaceuticals - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 1.06 | 0.80 |
| Quick Ratio | 1.61 | 0.85 | 0.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥639.55 Million | CN¥54.68 Million | CN¥-553.71 Million |
Harbin Gloria Pharmaceuticals - Advanced Valuation Insights
This section examines the relationship between Harbin Gloria Pharmaceuticals's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.10 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 11.0% |
| Total Assets | CN¥3.13 Billion |
| Market Capitalization | $1.13 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Harbin Gloria Pharmaceuticals's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Harbin Gloria Pharmaceuticals's assets grew by 11.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Harbin Gloria Pharmaceuticals (2007–2025)
The table below shows the annual total assets of Harbin Gloria Pharmaceuticals from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.13 Billion ≈ $458.69 Million |
+10.95% |
| 2024-12-31 | CN¥2.83 Billion ≈ $413.40 Million |
-10.38% |
| 2023-12-31 | CN¥3.15 Billion ≈ $461.30 Million |
-22.62% |
| 2022-12-31 | CN¥4.07 Billion ≈ $596.18 Million |
-13.23% |
| 2021-12-31 | CN¥4.70 Billion ≈ $687.05 Million |
+3.96% |
| 2020-12-31 | CN¥4.52 Billion ≈ $660.88 Million |
-29.52% |
| 2019-12-31 | CN¥6.41 Billion ≈ $937.63 Million |
-32.39% |
| 2018-12-31 | CN¥9.48 Billion ≈ $1.39 Billion |
+4.56% |
| 2017-12-31 | CN¥9.06 Billion ≈ $1.33 Billion |
+4.59% |
| 2016-12-31 | CN¥8.67 Billion ≈ $1.27 Billion |
+4.19% |
| 2015-12-31 | CN¥8.32 Billion ≈ $1.22 Billion |
+68.99% |
| 2014-12-31 | CN¥4.92 Billion ≈ $720.29 Million |
+67.26% |
| 2013-12-31 | CN¥2.94 Billion ≈ $430.65 Million |
+14.75% |
| 2012-12-31 | CN¥2.56 Billion ≈ $375.28 Million |
+10.91% |
| 2011-12-31 | CN¥2.31 Billion ≈ $338.36 Million |
+5.37% |
| 2010-12-31 | CN¥2.19 Billion ≈ $321.12 Million |
+395.95% |
| 2009-12-31 | CN¥442.48 Million ≈ $64.75 Million |
+58.47% |
| 2008-12-31 | CN¥279.21 Million ≈ $40.86 Million |
+29.56% |
| 2007-12-31 | CN¥215.51 Million ≈ $31.54 Million |
-- |
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more